272 related articles for article (PubMed ID: 34942444)
1. Therapeutic targeting of "undruggable" MYC.
Llombart V; Mansour MR
EBioMedicine; 2022 Jan; 75():103756. PubMed ID: 34942444
[TBL] [Abstract][Full Text] [Related]
2. Mission Possible: Advances in MYC Therapeutic Targeting in Cancer.
Allen-Petersen BL; Sears RC
BioDrugs; 2019 Oct; 33(5):539-553. PubMed ID: 31392631
[TBL] [Abstract][Full Text] [Related]
3. Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.
Wang H; Teriete P; Hu A; Raveendra-Panickar D; Pendelton K; Lazo JS; Eiseman J; Holien T; Misund K; Oliynyk G; Arsenian-Henriksson M; Cosford ND; Sundan A; Prochownik EV
Oncotarget; 2015 Oct; 6(32):32380-95. PubMed ID: 26474287
[TBL] [Abstract][Full Text] [Related]
4. The Molecular 'Myc-anisms' Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics.
McAnulty J; DiFeo A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322239
[No Abstract] [Full Text] [Related]
5. Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer.
Li B; Simon MC
Clin Cancer Res; 2013 Nov; 19(21):5835-41. PubMed ID: 23897900
[TBL] [Abstract][Full Text] [Related]
6. The Myc oncoprotein as a therapeutic target for human cancer.
Vita M; Henriksson M
Semin Cancer Biol; 2006 Aug; 16(4):318-30. PubMed ID: 16934487
[TBL] [Abstract][Full Text] [Related]
7. MYC in liver cancer: mechanisms and targeted therapy opportunities.
Liu F; Liao Z; Zhang Z
Oncogene; 2023 Nov; 42(45):3303-3318. PubMed ID: 37833558
[TBL] [Abstract][Full Text] [Related]
8. Taking on challenging targets: making MYC druggable.
Horiuchi D; Anderton B; Goga A
Am Soc Clin Oncol Educ Book; 2014; ():e497-502. PubMed ID: 24857145
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cIAP1 as a strategy for targeting c-MYC-driven oncogenic activity.
Li H; Fang Y; Niu C; Cao H; Mi T; Zhu H; Yuan J; Zhu J
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):E9317-E9324. PubMed ID: 30181285
[TBL] [Abstract][Full Text] [Related]
10. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
11. Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters.
Gan L; Xiu R; Ren P; Yue M; Su H; Guo G; Xiao D; Yu J; Jiang H; Liu H; Hu G; Qing G
Oncogene; 2016 Jun; 35(23):3037-48. PubMed ID: 26434591
[TBL] [Abstract][Full Text] [Related]
12. The long journey to bring a Myc inhibitor to the clinic.
Whitfield JR; Soucek L
J Cell Biol; 2021 Aug; 220(8):. PubMed ID: 34160558
[TBL] [Abstract][Full Text] [Related]
13. Cell-Based Methods for the Identification of Myc-Inhibitory Small Molecules.
Burkhart CA; Haber M; Norris MD; Gudkov AV; Nikiforov MA
Methods Mol Biol; 2021; 2318():337-346. PubMed ID: 34019301
[TBL] [Abstract][Full Text] [Related]
14. Attacking c-Myc: targeted and combined therapies for cancer.
Huang H; Weng H; Zhou H; Qu L
Curr Pharm Des; 2014; 20(42):6543-54. PubMed ID: 25341931
[TBL] [Abstract][Full Text] [Related]
15. Drugging "undruggable" genes for cancer treatment: Are we making progress?
Duffy MJ; Crown J
Int J Cancer; 2021 Jan; 148(1):8-17. PubMed ID: 32638380
[TBL] [Abstract][Full Text] [Related]
16. Cell-based methods for the identification of MYC-inhibitory small molecules.
Burkhart CA; Haber M; Norris MD; Gudkov AV; Nikiforov MA
Methods Mol Biol; 2013; 1012():255-64. PubMed ID: 24006071
[TBL] [Abstract][Full Text] [Related]
17. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
Liu X; Xiao XY; Shou QY; Yan JF; Chen L; Fu HY; Wang JC
J Ethnopharmacol; 2016 Dec; 193():538-545. PubMed ID: 27686271
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches.
Carabet LA; Rennie PS; Cherkasov A
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30597997
[TBL] [Abstract][Full Text] [Related]
19. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.
Huang MJ; Cheng YC; Liu CR; Lin S; Liu HE
Exp Hematol; 2006 Nov; 34(11):1480-9. PubMed ID: 17046567
[TBL] [Abstract][Full Text] [Related]
20. The c-MYC oncoprotein as a treatment target in cancer and other disorders of cell growth.
Pelengaris S; Khan M
Expert Opin Ther Targets; 2003 Oct; 7(5):623-42. PubMed ID: 14498825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
